| Dr Ryan M Ilgenfritz, MD | |
|
13535 Nemours Pkwy, Orlando, FL 32827-7402 | |
| (407) 567-4000 | |
| (302) 651-4945 |
| Full Name | Dr Ryan M Ilgenfritz |
|---|---|
| Gender | Male |
| Speciality | Orthopaedic Surgery - Pediatric Orthopaedic Surgery |
| Location | 13535 Nemours Pkwy, Orlando, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093923450 | NPI | - | NPPES |
| 013636800 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XP3100X | Orthopaedic Surgery - Pediatric Orthopaedic Surgery | ME119700 (Florida) | Primary |
| Entity Name | The Nemours Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386658615 PECOS PAC ID: 9537072483 Enrollment ID: O20040109000252 |
News Archive
Aeris Therapeutics, a company specializing in the development and commercialization of novel treatments for patients with emphysema and other advanced lung diseases, today announced that it has received CE Mark approval for its AeriSeal System.
KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that it has initiated a first-in-human, proof-of-concept study evaluating the safety, tolerability, persistence and histological effects of ATX-104, a light-activated facial contouring agent.
VBL Therapeutics today announced positive results from preclinical and Phase 1 studies evaluating the company's lead anti-cancer agent, VB-111 - a first-in-class, targeted biological agent shown to work via dual-action, anti-angiogenic and vascular disruptive mechanism of action - in metastatic cancer. Preclinical data evaluating VB-111 in a comprehensive set of in vivo studies employing the Lewis Lung metastasis mouse model showed the compound to be safe and specific, with a 90% reduction in tumor burden of lung metastases after only one injection.
Corventis, Inc., a developer of wireless cardiovascular solutions, announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its NUVANT™ Mobile Cardiac Telemetry (MCT) System for the detection of non-lethal arrhythmias. In addition, the company announced that its Monitoring Center has been approved by the Center for Medicare & Medicaid Services (CMS) as an Independent Diagnostic Testing Facility (IDTF). Corventis has also received approval to bill for services provided to patients with Medicare and several commercial insurers, paving the way for the NUVANT MCT System to be available across the United States.
EKF Diagnostics, the global diagnostics business, announces the launch of the new version of its Lactate Scout+ analyzer.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ryan M Ilgenfritz, MD Po Box 191, Rockland, DE 19732-0191 Ph: (302) 651-4000 | Dr Ryan M Ilgenfritz, MD 13535 Nemours Pkwy, Orlando, FL 32827-7402 Ph: (407) 567-4000 |
News Archive
Aeris Therapeutics, a company specializing in the development and commercialization of novel treatments for patients with emphysema and other advanced lung diseases, today announced that it has received CE Mark approval for its AeriSeal System.
KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that it has initiated a first-in-human, proof-of-concept study evaluating the safety, tolerability, persistence and histological effects of ATX-104, a light-activated facial contouring agent.
VBL Therapeutics today announced positive results from preclinical and Phase 1 studies evaluating the company's lead anti-cancer agent, VB-111 - a first-in-class, targeted biological agent shown to work via dual-action, anti-angiogenic and vascular disruptive mechanism of action - in metastatic cancer. Preclinical data evaluating VB-111 in a comprehensive set of in vivo studies employing the Lewis Lung metastasis mouse model showed the compound to be safe and specific, with a 90% reduction in tumor burden of lung metastases after only one injection.
Corventis, Inc., a developer of wireless cardiovascular solutions, announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its NUVANT™ Mobile Cardiac Telemetry (MCT) System for the detection of non-lethal arrhythmias. In addition, the company announced that its Monitoring Center has been approved by the Center for Medicare & Medicaid Services (CMS) as an Independent Diagnostic Testing Facility (IDTF). Corventis has also received approval to bill for services provided to patients with Medicare and several commercial insurers, paving the way for the NUVANT MCT System to be available across the United States.
EKF Diagnostics, the global diagnostics business, announces the launch of the new version of its Lactate Scout+ analyzer.
› Verified 5 days ago
Dr. Nam Dinh, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5979 Vineland Rd Ste 101, Orlando, FL 32819 Phone: 407-355-3120 | |
Bryan David Brown, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1222 S Orange Ave, 5th Floor, Orlando, FL 32806 Phone: 321-841-1764 Fax: 321-841-1870 | |
Dr. Michael David Riggenbach, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 25 W Crystal Lake St, Suite 200, Orlando, FL 32806 Phone: 407-254-2500 Fax: 407-423-2789 | |
George John Haidukewych, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 89 W Copeland Dr, 3rd Floor, Orlando, FL 32806 Phone: 407-649-6878 Fax: 407-843-7381 | |
Vonda Joy Wright, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 6775 Chopra Terrace, Suite 300, Orlando, FL 32827 Phone: 689-216-8000 | |
Dr. Joseph D Funk, DPM Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 25 W Crystal Lake St, Suite 200, Orlando, FL 32806 Phone: 407-254-2500 Fax: 407-254-2557 | |
Dr. Bensen Benjamin Fan, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 1222 S Orange Ave Fl 5, Orlando, FL 32806 Phone: 844-362-1735 Fax: 321-841-3040 |